BIRD FLU ROUND UP, BIRD FLU VACCINE, GERMANY FRANCE BRITAIN
April 1st, 2006
BY KEITH NUTHALL
MASS production of a vaccine to fight the H5N1 bird flu strain in humans could begin within a year, after pharmaceuticals giant GlaxoSmithKline launched clinical trials in Germany and Belgium.
The company is testing two vaccines: the first would be targeted at fighting a pandemic after an outbreak; the second aimed at advance inoculations.
Glaxo flu operations chief Emmanuel Hanon said: "We believe that vaccinating populations with the appropriate H5N1 vaccine will help educate the body's immune system and reduce expected morbidity and ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.